Southeastern Asset Management Inc. TN Has $101.34 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Southeastern Asset Management Inc. TN lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 308,469 shares of the medical research company's stock after selling 9,867 shares during the period. Bio-Rad Laboratories comprises about 4.8% of Southeastern Asset Management Inc. TN's investment portfolio, making the stock its 8th biggest holding. Southeastern Asset Management Inc. TN owned 1.10% of Bio-Rad Laboratories worth $101,335,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Bio-Rad Laboratories by 33.4% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,909 shares of the medical research company's stock valued at $627,000 after buying an additional 478 shares during the period. ProShare Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 8.0% during the 4th quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after buying an additional 67 shares during the period. Quantinno Capital Management LP boosted its stake in shares of Bio-Rad Laboratories by 552.0% during the 4th quarter. Quantinno Capital Management LP now owns 7,850 shares of the medical research company's stock valued at $2,579,000 after buying an additional 6,646 shares during the period. Man Group plc acquired a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $2,535,000. Finally, Nomura Holdings Inc. acquired a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $1,004,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BIO shares. Royal Bank of Canada dropped their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Citigroup dropped their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. UBS Group dropped their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $327.40.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded down $0.48 during trading hours on Monday, reaching $248.19. 196,883 shares of the company were exchanged, compared to its average volume of 320,188. The firm has a market cap of $6.95 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $243.46 and a 200 day moving average of $298.10. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The firm had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The company's revenue was down 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.30 earnings per share. As a group, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.